finance.yahoo.com ·
rigel pharmaceuticals inks breast cancer 203107776
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedRigel Pharmaceuticals gains exclusive global rights to VEPPANU, an FDA-approved oral PROTAC for breast cancer. Rigel will invest up to $40M in development over four years. The drug targets a specific patient population (ESR1-mutated) and showed superior efficacy in Phase 3. This creates a revenue growth opportunity for Rigel, with potential to capture market share in the ER+/HER2- breast cancer segment. The licensing deal involves Arvinas (originator) and Pfizer (co-owner).
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Rigel Pharmaceuticals entered exclusive global licensing agreement with Arvinas and Pfizer for oral PROTAC drug VEPPANU (vepdegestrant).
- Rigel plans to contribute up to $40 million towards development over four years.
- VEPPANU received FDA approval in May 2026 for ER+/HER2- ESR1-mutated advanced/metastatic breast cancer.
- Phase 3 VERITAC-2 trial showed 43% reduction in disease progression risk vs fulvestrant.
- Agreement positions Rigel to launch VEPPANU in U.S. and pursue global rights.
VEPPANU revenue growth for Rigel expected to increase modestly over 1-4 weeks; impact magnitude 2. Key risk: competition from other therapies may limit market share and reimbursement hurdles could delay revenue.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- GLOBAL_HEALTHCAREmid
- GLOBAL_HEALTHCAREshort
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
finance.yahoo.com
oncology institute q1 earnings call 050614985
economictimes.indiatimes.com
zydus lifesciences shares jump 6 on buyback buzz co announces 166 mn assertio acquisition
finance.yahoo.com
transcript valneva q1 2026 earnings 155143868
aol.com